What researchers published on Mezotelióma
6203 papers, newest first.
Showing 20 of 187
Vizsgálati eredményPreclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.Nature communications
Vizsgálati eredményCHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma.Clinical lung cancer
Randomizált vizsgálatGemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study.BMC cancer
Vizsgálati eredményPhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection.The Journal of thoracic and cardiovascular surgery
Randomizált vizsgálatFive-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Vizsgálati eredményPembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial.Clinical lung cancer
Randomizált vizsgálatEvaluation of an educational program for nurses on the care coordination of pleural mesothelioma patients: A pilot randomized controlled trial.Japan journal of nursing science : JJNS
Vizsgálati eredményPhase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.Molecular therapy : the journal of the American Society of Gene Therapy
Randomizált vizsgálatNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG).Lung cancer (Amsterdam, Netherlands)
Vizsgálati eredményPembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.The Lancet. Oncology
Vizsgálati eredményFirst-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors.ESMO open
Vizsgálati eredményYAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.Nature medicine
Vizsgálati eredményPerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.Nature medicine
Randomizált vizsgálatA randomized comparative study on maintenance gemcitabine versus supportive care in pleural mesothelioma.Future oncology (London, England)
Vizsgálati eredményKEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.Cancer science
Vizsgálati eredményEfficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma.Lung cancer (Amsterdam, Netherlands)
Vizsgálati eredményAd-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research
Randomizált vizsgálatEvaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer.Clinical and translational science
Vizsgálati eredményWT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.Journal of hematology & oncology
Randomizált vizsgálatA randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.Annals of oncology : official journal of the European Society for Medical Oncology